Sign In
Buy OKYO
$1.55
+0.0700 (+4.73%)
At Close: Jul 24, 2026
OKYO Pharma to present Phase 2 dry eye disease trial data at TFOS conference
09:38am, Wednesday, 30'th Oct 2024
OKYO Pharma Ltd (NASDAQ:OKYO) announced it will present at the 10th International Tear Film & Ocular Surface Society (TFOS) Conference in Venice, Italy, being held from October 30 to November 2, 2024
OKYO Pharma doses first patient in Phase 2 neuropathic corneal pain trial - ICYMI
10:22am, Saturday, 26'th Oct 2024
OKYO Pharma Ltd (NASDAQ:OKYO) CEO Gary Jacob joined Proactive to discuss recent developments in the company's Phase 2 clinical trial for OK-101, an investigational therapy targeting neuropathic cornea
OKYO Pharma doses first patient in Phase 2 neuropathic corneal pain trial
09:40am, Wednesday, 23'rd Oct 2024
OKYO Pharma Ltd (NASDAQ:OKYO) announced that the first patient has been dosed in the Phase 2 trial of its investigational therapeutic topical OK-101 to treat neuropathic corneal pain (NCP). NCP, which
OKYO Pharma Announces First Patient Dosed in the First Clinical Trial to Treat Neuropathic Corneal Pain
07:00am, Wednesday, 23'rd Oct 2024
LONDON and NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), an ophthalmology-focused bio-pharmaceutical company which is developing OK-101 to treat corneal neuropathic p
OKYO Pharma begins Phase 2 trial for neuropathic corneal pain treatment
09:26am, Wednesday, 16'th Oct 2024
OKYO Pharma Ltd (NASDAQ:OKYO) has started recruiting patients for its Phase 2 trial of its ocular therapy OK-101, aimed at treating neuropathic corneal pain (NCP). The trial comes as part of OKYO's br
OKYO Pharma secures key US patent for dry eye disease therapy
08:43am, Tuesday, 27'th Aug 2024
OKYO Pharma Ltd (NASDAQ:OKYO) announced it has been granted a US patent covering claims on its investigational therapeutic OK-101's use to treat irritated, burning eyes and blurred vision in patients
OKYO Pharma CEO Interview to Air on Bloomberg TV
09:00am, Friday, 23'rd Aug 2024
LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflam
OKYO Pharma and SolarMax Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
09:00am, Friday, 23'rd Aug 2024
ORLANDO, FL / ACCESSWIRE / August 23, 2024 / RedChip Companies will air interviews with OKYO Pharma Ltd. (Nasdaq:OKYO) and SolarMax Technology, Inc. (Nasdaq:SMXT) on the RedChip Small Stocks, Big Mone
OKYO Pharma Announces Chairman Acquires Shares
07:00am, Friday, 23'rd Aug 2024
LONDON and NEW YORK, Aug. 23, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflam
OKYO Pharma chairman acquires more shares in the company
08:35am, Wednesday, 21'st Aug 2024
OKYO Pharma Ltd (NASDAQ:OKYO) announced that it has been notified that Panette Partners Limited, an entity in which its chairman Gabriele Cerrone has a beneficial interest, has purchased 35,000 shares
OKYO Pharma Announces Chairman Acquires Shares
07:00am, Wednesday, 21'st Aug 2024
LONDON and NEW YORK, Aug. 21, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflam
OKYO Pharma Participates in H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
12:13pm, Thursday, 15'th Aug 2024
LONDON and NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflam
OKYO Pharma lands European patent protection for lead asset
08:40am, Tuesday, 06'th Aug 2024
OKYO Pharma Ltd (NASDAQ:OKYO) has been granted a European patent for its lead asset, OK-101. Entitled Compositions Comprising Chemerin Analogs and Methods of Use, it covers OK-101 chemerin analogs, st
OKYO Pharma Granted European Patent Covering OK-101 Chemerin Analogs and Their Method of Use
07:00am, Tuesday, 06'th Aug 2024
LONDON and NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflam
OKYO Pharma dry eye disease trial to get underway in the third quarter
08:41am, Thursday, 11'th Jul 2024
OKYO Pharma Ltd (NASDAQ:OKYO) plans to begin a phase II clinical trial for OK-101, targeting neuropathic corneal pain (NCP), in the third quarter. In earlier studies, OK-101 showed significant pain re
